BioAge reports Q2 2026 results, first patient dosed in Phase 2 QUELL-CV trial
The company also plans a second BGE-102 study in diabetic eye disease and reported $381.3 million in cash as of June 30.
SEC filing
Latest
2 stories
Sign inSign in2 stories
The company also plans a second BGE-102 study in diabetic eye disease and reported $381.3 million in cash as of June 30.
SEC filing